Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The ...
Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa The following ...
The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results